How to Get Finasteride in South Dakota

What Finasteride Is and Why South Dakota Residents Use It

Finasteride is a 5-alpha-reductase type II inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). The FDA approved the 1 mg tablet (Propecia) for male androgenetic alopecia (AGA) in 1997 and the 5 mg tablet (Proscar) for benign prostatic hyperplasia (BPH) in 1992. Both approvals remain active on the FDA label accessible via the agency's drug database [1].

South Dakota's age-adjusted rate of male AGA mirrors the national prevalence, which affects roughly 50% of men by age 50 according to data catalogued in the American Academy of Dermatology's epidemiology literature [2]. BPH is similarly common: the NIH estimates that more than 50% of men in their 60s show histologic BPH [3].

DHT is the dominant androgen driving both miniaturization of scalp follicles and prostatic stromal proliferation [4]. Finasteride reduces serum DHT by approximately 65% to 70% at the 1 mg dose and by roughly 70% to 75% at 5 mg [1]. That biochemical suppression is the basis for every clinical benefit described below.

Clinical Evidence Supporting Finasteride

The evidence base for finasteride is well-established across multiple randomized controlled trials. Kaufman et al. (1998, N=1,553, 2-year phase III RCT) reported that 1 mg finasteride daily increased scalp hair count by a mean of 107 hairs per 1 cm² target area versus a loss of 23 hairs in the placebo group at 24 months (P<0.001) [5]. Investigator-assessed hair growth was rated improved or greatly improved in 66% of finasteride recipients vs. 7% of placebo recipients at 2 years [5].

A landmark 5-year extension study by Kaufman et al. (J Am Acad Dermatol 1998) confirmed that continuous 1 mg daily use maintained scalp hair count above baseline across the full 60-month observation window, whereas placebo recipients continued losing hair at a rate consistent with natural AGA progression [5]. Discontinuation reverses the drug's DHT-suppressive effect within 6 to 12 months, and hair loss resumes [6].

For BPH, the PLESS trial (Proscar Long-term Efficacy and Safety Study, N=3,040 to 4 years) showed that finasteride 5 mg reduced prostate volume by 18% and the risk of acute urinary retention by 57% compared with placebo [7]. The American Urological Association's BPH guidelines cite PLESS among foundational evidence for 5-alpha-reductase inhibitor therapy [8].

Sexual side effects occur in approximately 3.8% of men taking 1 mg finasteride versus 2.1% in placebo arms across pooled phase III data [5]. PSA levels fall by approximately 50% after 6 months on 5 mg finasteride; clinicians must double any PSA reading taken on-drug to estimate the true unmedicated value when screening for prostate cancer [1].

How to Get a Finasteride Prescription in South Dakota

Getting finasteride in South Dakota requires a valid prescription from a licensed prescriber. The state does not impose any finasteride-specific restrictions beyond federal law, so the process mirrors the national standard: schedule an appointment, complete a medical history, receive a prescription, fill it at a pharmacy.

South Dakota follows the federal definition of a valid prescription under 21 CFR 1300 et seq. [9]. A prescriber licensed by the South Dakota Board of Medical and Osteopathic Examiners (SDBMOE) or the South Dakota Board of Nursing (for advanced practice providers) must issue the prescription. The prescription may be transmitted electronically, by fax, or as a paper document to any pharmacy registered with the South Dakota Board of Pharmacy [10].

Three practical paths exist for South Dakota residents:

In-person visit. A primary care physician, urologist, or dermatologist practicing anywhere in South Dakota can prescribe finasteride after a standard clinical evaluation. Cities with active dermatology and urology practices include Sioux Falls, Rapid City, Aberdeen, and Brookings.

Telehealth visit. South Dakota enacted its telehealth parity statute under SDCL 58-17-144, which requires insurers to cover telehealth services comparably to in-person care [11]. A prescriber holding an active South Dakota license can conduct a synchronous audio-video evaluation and issue a finasteride prescription without an in-person encounter. National telehealth platforms that hold South Dakota provider licenses are legally permitted to do this.

Transfer of an existing prescription. Patients moving to South Dakota with an existing finasteride prescription can transfer unexpired refills to any South Dakota-registered pharmacy, subject to the pharmacy's verification of the original prescriber's licensure. If refills are exhausted, a new evaluation is required.

Telehealth Finasteride in South Dakota: What to Expect

Telehealth prescribing for finasteride is legal and operational in South Dakota. The visit typically takes 10 to 20 minutes. A licensed clinician reviews the patient's medical history, current medications, PSA history (for men over 40 or those with BPH symptoms), and photographs of hair loss pattern for AGA cases.

The South Dakota Medical Practice Act (SDCL 36-4) does not require a prior in-person relationship before a telehealth prescriber can issue a prescription, provided the clinician conducts a real-time audio-video evaluation sufficient to establish a patient-provider relationship and make a clinical determination [12]. This aligns with the Federation of State Medical Boards' Model Policy for the Appropriate Use of Telemedicine [13].

After the visit, the prescription is sent electronically to the patient's pharmacy of choice. Shipping timelines from mail-order pharmacies to South Dakota addresses are typically 3 to 7 business days for standard delivery. Local pharmacies in Sioux Falls and Rapid City generally stock generic finasteride and can fill same-day or next-day.

The HealthRX clinical team uses a structured intake framework for finasteride telehealth evaluations in states including South Dakota. The framework follows four decision nodes: (1) confirm AGA or BPH indication via validated scoring (Norwood-Hamilton scale for AGA, IPSS score for BPH); (2) screen for contraindications including 5-alpha-reductase inhibitor hypersensitivity and pregnancy potential in household contacts; (3) obtain or order baseline PSA and liver function tests for men over 40 before prescribing; (4) document shared decision-making regarding sexual side effects, PSA interpretation, and the need for continuous use to maintain benefit.

Labs Required Before Starting Finasteride in South Dakota

No federal or South Dakota state law mandates specific laboratory testing before finasteride dispensing. Clinical practice guidelines, however, recommend baseline testing for certain patients. The American Urological Association recommends a baseline PSA measurement before initiating 5-alpha-reductase inhibitor therapy in men with BPH or prostate cancer risk factors [8]. The FDA label for finasteride 5 mg states that PSA should be established at baseline and monitored during treatment [1].

For AGA patients under 40 without BPH symptoms, a PSA is not universally required but may be ordered at prescriber discretion. A liver function panel (AST, ALT, bilirubin) is reasonable given finasteride's hepatic metabolism via CYP3A4, though clinically significant hepatotoxicity is rare at therapeutic doses [14]. Testosterone and DHT levels are not required for prescribing but provide a useful baseline if monitoring is planned.

Baseline labs can be ordered through any South Dakota-licensed laboratory. Quest Diagnostics and LabCorp both operate draw sites in Sioux Falls and Rapid City, with results typically available within 24 to 48 hours. Telehealth providers can order labs electronically for South Dakota patients, and results are reviewed before the prescription is finalized or on a scheduled follow-up visit.

Finasteride Pharmacies in South Dakota: Retail, Mail-Order, and 503A Compounding

Any pharmacy holding a valid South Dakota Board of Pharmacy retail license can dispense FDA-approved generic finasteride tablets. Generic 1 mg finasteride is available at chain pharmacies including CVS, Walgreens, and Walmart locations throughout Sioux Falls, Rapid City, and other South Dakota cities. GoodRx pricing for a 30-day supply of generic 1 mg finasteride in the Sioux Falls 57104 area has ranged from approximately $10 to $22 depending on the pharmacy, based on publicly available pharmacy benefit data [15].

Mail-order pharmacies registered to ship to South Dakota can provide 90-day supplies, often at lower per-unit cost. Patients should confirm the mail-order pharmacy holds an active South Dakota non-resident pharmacy permit issued by the South Dakota Board of Pharmacy.

503A compounding pharmacies may prepare customized finasteride formulations (for example, topical finasteride solutions) for individual patients when a prescriber writes a patient-specific order. A 503A pharmacy must hold a South Dakota registration or a non-resident 503A permit to ship to South Dakota patients. The FDA's guidance on 503A compounding under the Drug Quality and Security Act (DQSA) distinguishes these from 503B outsourcing facilities, which produce larger non-patient-specific batches [16]. Topical finasteride compounded by a 503A pharmacy is not FDA-approved and is dispensed on the basis of a valid prescription for an identified patient.

South Dakota Medicaid does not cover finasteride prescribed for androgenetic alopecia (a cosmetic indication) or for BPH as of the 2024-2025 South Dakota Medicaid fee schedule. Patients relying on Medicaid coverage should confirm current formulary status with their managed care plan, as formularies may change [17].

Who Can Prescribe Finasteride in South Dakota

Several categories of licensed providers can write a valid finasteride prescription in South Dakota. The relevant licensing boards and statutory authority are:

Medical doctors (MD) and doctors of osteopathic medicine (DO) licensed by the South Dakota Board of Medical and Osteopathic Examiners under SDCL 36-4 have full prescriptive authority for finasteride [12]. This includes primary care physicians, dermatologists, urologists, and endocrinologists practicing in South Dakota.

Nurse practitioners (NP) holding a South Dakota APRN license and a collaborative agreement (or independent practice status under SD's updated APRN statutes) may prescribe finasteride within their scope of practice, which includes men's health and primary care conditions [18]. South Dakota revised its APRN practice statute to allow independent prescribing after a transition-to-practice period, making telehealth-based NP prescribing broadly available.

Physician assistants (PA) licensed by the South Dakota Board of Medical and Osteopathic Examiners under SDCL 36-4A may prescribe finasteride in collaboration with a supervising physician, consistent with their practice agreement [12].

The prescriber does not need to be physically located in South Dakota to prescribe to a South Dakota patient via telehealth, but the prescriber must hold an active South Dakota license (or a telemedicine-specific license if available) and comply with SD telehealth statutes [11].

Prior Authorization for Finasteride in South Dakota

Prior authorization (PA) requirements depend on the patient's insurance plan, not state law directly. For BPH-indicated finasteride, commercial insurers in South Dakota vary in their requirements. Some plans cover generic finasteride for BPH without prior authorization; others require documentation of symptom severity (IPSS score of 8 or above is a common threshold), prostate volume measurement, or a trial of an alpha-blocker first.

For AGA, most commercial plans classify finasteride as a cosmetic benefit exclusion and will not cover it regardless of prior authorization documentation. Patients pursuing PA for BPH coverage should gather the following before submission: (1) IPSS questionnaire score, (2) PSA value and date, (3) prescriber's clinical notes documenting BPH diagnosis and symptom impact, and (4) any prior alpha-blocker trial history with dates and discontinuation reasons.

The Centers for Medicare and Medicaid Services (CMS) publishes prior authorization guidance applicable to Medicare Advantage plans that may cover finasteride for BPH under certain formulary tiers [19]. South Dakota Medicare Advantage enrollees should verify Part D formulary placement using the CMS Plan Finder tool before assuming coverage.

Dosing, Administration, and Duration of Use

For androgenetic alopecia, the FDA-approved dose is 1 mg orally once daily. The tablet may be taken with or without food. Hair count improvements are detectable by standardized trichoscopy at 6 months in some patients, though the landmark Kaufman 2-year trial showed maximal statistical benefit at 24 months of continuous use [5]. Men who stop finasteride lose accumulated hair benefit within 6 to 12 months, as DHT levels return to baseline after discontinuation [6].

For BPH, the approved dose is 5 mg orally once daily. Prostate volume reduction becomes clinically significant at 3 to 6 months, and the PLESS trial demonstrated continued benefit through 48 months [7]. Combination therapy with an alpha-blocker (for example, tamsulosin 0.4 mg daily) is supported by the CombAT trial (N=3,047), which showed that the finasteride-dutasteride combination group (a design variant) reduced BPH clinical progression risk by 66% versus alpha-blocker monotherapy at 4 years [20]. While CombAT used dutasteride rather than finasteride, the AUA guideline extends combination therapy recommendations to finasteride as well [8].

The FDA label includes a boxed warning that pregnant women or women who may become pregnant must not handle crushed or broken finasteride tablets because of the risk of feminization of a male fetus [1]. Whole tablets are coated and safe to handle; the warning applies specifically to crushed or broken tablets.

Side Effects and Monitoring

Sexual side effects are the most discussed adverse event. The pooled phase III data for 1 mg finasteride (N=945 finasteride, N=934 placebo, 12 months) show decreased libido in 1.8% vs. 1.3%, erectile dysfunction in 1.3% vs. 0.7%, and ejaculation disorder in 1.2% vs. 0.7% [5]. The absolute rate differences are small. Most cases resolved after stopping finasteride; a minority of patients in post-marketing surveillance have reported persistent sexual dysfunction after discontinuation, though a causal relationship has not been confirmed in controlled trials [6].

Breast tenderness or gynecomastia occurs in approximately 0.5% of men at 1 mg and should prompt clinical evaluation if it develops [5]. Patients with a first-degree relative with prostate cancer, or who are of African ancestry (a population at higher prostate cancer risk), should ensure their prescriber accounts for the PSA interpretation adjustment (multiply on-drug PSA by 2) before any prostate cancer screening decision [1].

Annual PSA monitoring is recommended for men using finasteride for BPH, consistent with AUA guidelines [8]. For AGA-only patients without prostate risk factors, monitoring frequency is at the prescriber's discretion, with most telehealth protocols scheduling a 3-month follow-up and then annual check-ins.

The FDA's Adverse Event Reporting System (FAERS) database contains post-marketing reports on finasteride; patients who experience unexpected adverse events can report them at MedWatch [21]. South Dakota clinicians are encouraged to submit FAERS reports for any serious or unlabeled adverse events they observe.